CEO turned informant: How the FDA built a case against executives promising cheap medications
Summary
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
Description from CNBC.
Who is covering this
-
CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.






Comments
Comments need JavaScript.